In those with a BMI ≥30 kg/m2, GLP-1 RA use was associated with a statistically significant lower risk of the primary composite outcome (HR: 0.72, 95% CI: 0.56–0.92) and first HF hospitalization (HR: 0.73, 95% CI: 0.56–0.95), and all the other outcomes except stroke/TIA and repeated HF hospitalizations. Here, GLP1R is linked to Stroke.